Video

Dr. Roeker on the Emerging Role of MRD in CLL

Lindsey Roeker, MD, discusses the emerging role of minimal residual disease as a predictive end point in chronic lymphocytic leukemia.

Lindsey Roeker, MD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the emerging role of minimal residual disease (MRD) as a predictive end point in chronic lymphocytic leukemia (CLL).

Understanding how to optimize MRD is developing in CLL, Roeker says. Clinical trials evaluating combined-modality regimens are including MRD as a predictive end point for response, Roeker explains.

A correlation between MRD negativity and prolonged progression-free survival (PFS) has been observed in patients with CLL treated with chemoimmunotherapy, Roeker says. Additionally, findings from the phase 3 MURANO trial (NCT02005471) demonstrated that undetectable MRD (uMRD) was associated with improved PFS, as well as overall survival, in patients with relapsed/refractory CLL, Roeker adds.

Additional research with ongoing trials is needed to determine whether uMRD can predict for long-term PFS benefit or whether fixed-duration treatment is a sufficient and simpler way to treat patients with CLL, Roeker concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina
Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity
Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas
Video

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

May 1st 2025 - Jun 6th 2025

online-activity
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

May 1st 2025 - May 2nd 2026

online-activity